<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03443037</url>
  </required_header>
  <id_info>
    <org_study_id>265-SBKAEK</org_study_id>
    <nct_id>NCT03443037</nct_id>
  </id_info>
  <brief_title>Benefits of Amantadine in Patients With Coma State</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dokuz Eylul University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dokuz Eylul University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was a single center observational-prospective study and approved by local ethics
      committee. Patients in coma state due to traumatic brain injury, cardiac arrest or ischemic
      stroke who are older than 18 years of age were included in the study. Patients who received
      amantadine 200mg/day for fourteen days according to ICU protocols decided by primary
      physician formed the amantadine group, and the rest of the subjects were included in the
      control group. All patients were evaluated for Glasgow Coma Score, JFK Coma Recovery Scale
      and Disability Rating Scale once a week for three months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2016</start_date>
  <completion_date type="Anticipated">July 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Glascow Coma Score</measure>
    <time_frame>1. At the time of enrollment 2. 12 weeks after the enrollment</time_frame>
    <description>Glascow Coma Score</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Coma; Prolonged</condition>
  <condition>Amantadine</condition>
  <arm_group>
    <arm_group_label>Amantadine group</arm_group_label>
    <description>Patients admitted to the critical care with diagnosis of coma state who have received amantadin 200 mg / day for fourteen days according to İCU protocols decided by primary physician</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Patients admitted to the critical care with diagnosis of coma state who haven't received amantadin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amantadine sulphate</intervention_name>
    <arm_group_label>Amantadine group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with the coma state duo to ischemic stroke, brain hemorhage, anoxic brain damage
        included in this study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18 years, ≤ 65 years

          -  GCS score ≤ 8

          -  Coma state due to ischemic stroke, brain hemorhage, anoxic brain damage

        Exclusion Criteria:

          -  &lt;18 years, &gt; 65 years

          -  Patients admitted to the critical care without diagnosis of coma state

          -  Patients admitted to critical care with coma state that are not duo to ischemic
             stroke, brain hemorhage, anoxic brain damage

          -  Metastatic malignant neoplazm

          -  Congenital or acquired brain function problem (cerebral palsy, autism etc)

          -  Patients with amantadine allergy

          -  Progressive degenerative diseases (Alzheimer, Parkinson diseases etc)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Necati Gokmen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dokuz Eylul University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kutlay Aydin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dokuz Eylul University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kutlay Aydin</last_name>
    <role>Study Director</role>
    <affiliation>Dokuz Eylul University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Begum Ergan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dokuz Eylul University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kutlay Aydin, MD</last_name>
    <phone>+905322649294</phone>
    <email>kutlayaydin@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dokuz Eylul University</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kutlay Aydin, MD</last_name>
      <phone>+905322649294</phone>
      <email>kutlayaydin@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Zehra Mermi, MD</last_name>
      <phone>+905331680832</phone>
      <email>zehramermi@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2018</study_first_submitted>
  <study_first_submitted_qc>February 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2018</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dokuz Eylul University</investigator_affiliation>
    <investigator_full_name>Begum Ergan</investigator_full_name>
    <investigator_title>Staff in the department of pulmonary and critical care medicine</investigator_title>
  </responsible_party>
  <keyword>Coma</keyword>
  <keyword>Disability</keyword>
  <keyword>amantadine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amantadine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

